On-body injectors segment by type is estimated to lead the market growth during the forecast period

According to a new market research study of “Europe Wearable injectors Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type Application and End User,” the Europe wearable injectors market is expected to reach US$ 3586.82 million in 2027 from US$ 1539.88 million in 2019. The market is estimated to grow with a CAGR of 11.3 % from 2020 to 2027. The growth of the market is driven by the factors such as, increasing chronic diseases prevalence, technological advancements and design development, and conventional drug delivery system limitations. However, the market is likely to have negative impact due to conventional drug delivery system limitations.

Based on type, the wearable injectors market is segmented into on-body injectors and off-body injectors. The on-body injectors segment held the largest share of the market in 2019. However, the off-body injectors segment is estimated to register the highest CAGR of 12.3% in the market during the forecast period.

An on-body injector is a wearable injection device. These devices are becoming popular with cancer patients in the wearable injectors market. Once the device is implemented to the stomach or arm, it slowly delivers the medication over some time. This allows patients to be treated at home without exposure to other infections during treatment. The convenience is making the wearable injectors one of the most in-demand in the forecast period.

The increasing prevalence of chronic diseases and the requirement for repeat dosing to treat these diseases are driving the market for off-body injectors. The off-body segment is estimated to attain favorable growth as these devices eliminate risks, such as painful removal of devices, adhesive fitting issues to the skin, and skin sensitivity or irritation. The pharmaceutical companies are increasingly focusing on the development of novel drug delivery devices to increase drug compliance and patient outcomes. This focus is on raising the bar for all players associated with the development and manufacturing of injectable products. For instance, Sensile Medical AG offers belt worn pump solution solutions for up to 20 ml for extended delivery time over several hours up to 3 days.

Europe wearable injectors Market is expected to grow owing to factors such as increasing chronic diseases prevalence, technological advancements and design development, and conventional drug delivery system. However, the market is likely to have negative impact due to preference of alternative drug delivery.

BD, CeQur SA, Debiotech S.A., E3D Elcam Drug Delivery Devices, Insulet Corporation, Gerresheimer AG, Tandem Diabetes Care Inc, Zealand Pharma A/S, West Pharmaceutical Services, Inc, Ypsomed AG, Medtronic, Amgen, Inc. Are among the leading companies operating in the Europe wearable injectors Market

The report segments Europe wearable injectors market as follows:

By Type

• On-body Injectors
• Off-body Injectors

By Application

• Diabetes
• Oncology
• Cardiovascular Disease
• Autoimmune Disease
• Other Applications

By End User

• Hospitals and Clinics
• Homecare Setting
• Other End User

By Country

• Germany
• UK
• Russia
• France
• Italy
• Spains
• Poland
• Netherlands
• Austria
• Switzerland